Adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Umeclidinium bromide leads to lower number of participants with exacerbations requiring steroids,… compared with placebo (high certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Umeclidinium bromide probably leads to higher quality of life: number of participants with ≥ 4 units improvement… compared with placebo (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Hospitalisations due to COPD exacerbations · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in number of participants with hospital admissions due to COPD… compared with placebo (low certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Umeclidinium bromide leads to higher number of participants with ≥ 1 unit improvement in TDI focal score compared with placebo (high certainty).
1 finding from 1 review
Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in adverse events (not including serious adverse events) compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Indacaterol leads to higher number of participants with a clinically significant improvement in… compared with placebo (high certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Indacaterol leads to higher number of participants with clinically significant improvement in… compared with placebo (high certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Indacaterol leads to lower number of participants experiencing 1 or more exacerbations compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations requiring oral corticosteroids ‐ School‐age children · School‐aged children and adults
Intermittent ICS showed no clear difference in exacerbations requiring oral corticosteroids ‐ School‐age children compared with placebo (low certainty).
1 finding from 1 review
QoL · Preschool children (<6 years)
1 finding from 1 review
Day time asthma score Standardised mean difference · Preschool children (<6 years)
1 finding from 1 review
Night time asthma score Mean difference · Preschool children (<6 years)
1 finding from 1 review
Adverse events · Preschool children (<6 years)
Intermittent ICS showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Exacerbations requiring oral corticosteroids ‐ adults · School‐aged children and adults
Intermittent ICS showed no clear difference in exacerbations requiring oral corticosteroids ‐ adults compared with placebo (low certainty).
1 finding from 1 review